Literature DB >> 6825131

Phase II evaluation of spirogermanium in advanced ovarian carcinoma.

D E Brenner, H W Jones, N B Rosenshein, A Forastiere, M Dillon, F Grumbine, S Tipping, L Burnett, F A Greco, P H Wiernik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6825131

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma.

Authors:  M L McMaster; F A Greco; D H Johnson; J D Hainsworth
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 3.  Complexes of metals other than platinum as antitumour agents.

Authors:  P Köpf-Maier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.